Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03819270 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of LY3372689 Given By Mouth to Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03819270 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 23 participants.
The verdict
NCT03819270, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is being conducted to determine the safety profile of the study drug after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3372689 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive up to 3 doses of LY3372689 or placebo. The study will last about 12 weeks, including screening.
Interventions
- DRUG Placebo
- DRUG LY3372689
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-02-05 |
| Est. Completion | 2019-06-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03819270
The ClinicalTrials.gov registry entry for NCT03819270 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03819270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03819270 about?
NCT03819270 is a clinical study titled "A Safety Study of LY3372689 Given By Mouth to Healthy Participants". This study is being conducted to determine the safety profile of the study drug after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3372689 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive...
What is the current status of trial NCT03819270?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2019-02-05. Estimated completion is 2019-06-24.
What interventions are being tested in trial NCT03819270?
The interventions under investigation include: Placebo (DRUG), LY3372689 (DRUG).
Who is sponsoring clinical trial NCT03819270?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.